



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 307/92, A61K 31/365	A1	(11) International Publication Number: WO 96/39401 (43) International Publication Date: 12 December 1996 (12.12.96)
(21) International Application Number: PCT/US96/08427 (22) International Filing Date: 3 June 1996 (03.06.96) (30) Priority Data: 479,049 6 June 1995 (06.06.95) US (71) Applicant: SHAMAN PHARMACEUTICALS, INC. [US/US]; 213 East Grand Avenue, South San Francisco, CA 94080 (US). (72) Inventors: INMAN, Wayne, D.; 101 Irencce Court #304, Belmont, CA 94002 (US). KING, Steven, R.; 191 Arbor Lane, P.O. Box 1052, Moss Beach, CA 94038 (US). EVANS, Joseph, L.; 1646 Filbert Street, San Francisco, CA 94123 (US). LUO, Jian; 240 Santa Clara Street, Brisbane, CA 94005 (US). (74) Agents: BALDWIN, Geraldine, F. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).		(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: FURANOEREMOPHILANE AND EREMOPHILANOLIDE SESQUITERPENES FOR TREATMENT OF DIABETES		
(57) Abstract Novel hypoglycemicly active eremophilanolide sesquiterpenes which can be isolated from <i>Psacalium spp.</i> , processes for obtaining the novel eremophilanolide sesquiterpenes and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes are described. Further described is the use of epicacalone, cacalone, cacalol or dimaturin as hypoglycemic agents, for examole, in the treatment of diabetes. In a preferred embodiment, the hypoglycemicly active compounds are obtained from the roots of <i>Psacalium decompositum</i> . As agents for the treatment of diabetes, the hypoglycemicly active compounds of the present inventions are useful for treating insulin-dependent (type I) and/or non-insulin-dependent (type II) diabetes.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**FURANOEREMOPHILANE AND EREMOPHILANOLIDE SESQUITERPENES
FOR TREATMENT OF DIABETES**

1. FIELD OF THE INVENTION

The present invention relates to a series of
5 furanoeremophilane and eremophilanolide sesquiterpenes,
including novel eremophilanolides, which exhibit hypoglycemic
and/or anti-diabetic activity in mammals, and provides
methods and compositions for their use, as well as processes
for their isolation.
10

2. BACKGROUND OF THE INVENTION

2.1 USES OF PSACALIUM SPP.


Plants of the genus *Psacalium* (syn. *Senecio*), e.g.
P. peltatum and *P. decompositum* (family Asteraceae, tribus
15 Senecioneae) are used in the United States, Mexico and other
parts of Central America, usually in the form of aqueous
decoctions, for the treatment of a variety of ailments
including diabetes, (e.g. R.J. Huxtable, *Proc. West.*
Pharmacol. Soc. 26, 185 (1983); R.M. Perez, G.A. Ocegueda,
20 J.L. Munoz, J.G. Avila, W.W. Morrow, *J. Ethnopharmacol.* 12,
253 (1984); R.A. Bye jr., *Econ. Bot.* 40, 103 (1986); M.
Winkelman, *Med. Anthropol.* 11, 255 (1989)). *P. decompositum*
is used by the following indigenous groups in Mexico: the
Tarahumara indigenous group of Sonora state use a root
25 decoction to treat diabetes mellitus and rheumatism (Atlas do
las Plantas Tradicionales de Mexicana, vol. 111, p. 185,
1994); the Yaqui indigenous group of the Sonora state treat
rheumatic pain in joints, gout, and skin ulcerations
(Herrera, A. Instituto Medico Nacional Vol. IX, 1907); the
30 Pima indigenous group of Sonora and Chihuahua states use a
warm or hot water extraction to treat colds, weak people with
poor appetites, and to strengthen blood (Flora Medicinale
Indigena de Mexico, vol. 1, INI, p. 124, 1994). Hypoglycemic
effects of aqueous and methanolic extracts of *P. peltatum*
35 were experimentally determined in mice (L. Sanchez, R. Roman,
F. Alarcon, J.L. Flores, R. Soto, 1994 Annual Meeting of the
Phytochemical Society of North America, Poster #63) and in

normal and alloxan-treated rabbits (R. Roman-Ramos, J.L. Flores-Saenz, G. Partida-Hernandez, A. Lara-Lemus, F. Alarcon-Aguilar, *Arch. Invest. Med. (Mex.)* 22, 87 (1991); *ibid.* 23, 105 (1992)), whereby it was found that the effect
5 was most pronounced in normal, non-diabetic animals.

Asteraceae plants of the *tribus* Senecioneae are rich in pyrrolizidine alkaloids (R. Hegnauer, "*Chemotaxonomie der Pflanzen*", Vol. VIII, pp. 280-281, Birkhäuser Verlag, Basel, 1989, and references cited therein), which because of
10 their pronounced hepatotoxicity, have been suspected to be the hypoglycemic agents in these plants (eg. R.J. Marles and N.R. Farnsworth in "*Econ. Med. Plant Res.*", Vol. VI, 149 (1994); E. Steinegger, R. Hänsel "*Lehrbuch der Pharmakognosie und Phytotherapie*", p.521, Springer Verlag 1988)).

15 While the presence of these compounds in *P. decompositum* has been verified by the inventors, no such compounds are present in any of the active extracts of this invention, nor are these compounds structurally in any way related to the antidiabetic compounds isolated from these
20 extracts and claimed herein.


Certain members of a class of furanoeremophilanes, not including, however, the novel antidiabetic compounds of the present invention have been isolated from members of the Senecioneae tribe (eg. F. Bohlmann, C. Zdero, D. Berger, A.
25 Suwita, P. Mahanta, C. Jeffrey, *Phytochemistry* 18, 79 (1979) and references cited therein). The furanoeremophilane skeleton is distinguished from other sesquiterpenes by the presence of the furano and decalin fused ring system along with two methyl groups at C-3 and C-5, and another methyl
30 group located at either C-4 or C-4a.



35

Oxidation of the furan to a lactone leads to the eremophilanolide skeletal type.

5



2.2 COMPOUNDS ISOLATED PREVIOUSLY FROM PSACALIUM SPP.

- 10 In the furanoeremophilane class, compounds such as cacalol and cacalone have been described. Cacalol and cacalone were originally isolated from *Cacalia decomposita* ((syn. *Parasenecio decomp.*) (J. Romo and P. Joseph-Nathan *Tetrahedron* 20, 2331 (1964)); after many revisions the
- 15 correct structure for cacalone was proposed based upon intensive n.m.r. analyses (K. Jankowski, E. Diaz, F. Yuste *Proc. Indian Acad. Sci. (Chem. Sci.)* 93, 1317 (1984)) and verified by X-ray crystallography (M. Soriano-Garcia, F. Walls, H. Barrios, R. Sanchez-Obregon, B. Ortiz, E. Diaz,
- 20 R.A. Toscano, F. Yuste *Acta Cryst. C* 44, 1092 (1988), and references cited therein); the absolute configuration for cacalol was determined to be 5S (M. Terabe, M. Tada, T. Takahashi *Bull. Chem. Soc. Jpn.* 51, 661 (1978)). The structures of epicacalone and adenostylide from *Cacalia*
- 25 *adenostyloides* were also determined previously (K. Omura, M. Nakanishi, K. Takai, K. Naya *Chem. Let.* 1978, 1257; M. Kuroyanagi, H. Naito, T. Noro, A. Ueno, S. Fukushima *Chem. Pharm. Bull.* 33, 4792 (1985)).

- Cacalol and its acetate show pronounced antioxidant
- 30 activity (N.P. Krasovskaya, N.I. Kulesh, V.A. Denisenko *Chem. Nat. Comp.* 25, 545 (1990)) and inhibit electron transport and phosphorylation in plant chloroplasts (B. Lotina-Hennsen, J.L. Roque-Resendiz, M. Jimenez, M. Aguilar *Z. Naturforsch. Ser. C* 46, 777 (1991)); the former effect was
- 35 weaker for cacalone. Cacalol and its acetyl- and acetate derivatives show weak antibacterial and antifungal effects in agar seeded assays (M. Jimenez, C. Lozano, J. Valdes, J.

Leon, G. Alacon, B. Sveshtarova *Rev. Latinoamer. Quim.* 23/1 and 22/4, 14 (1992)).

To the best of the inventors knowledge, no prior study has described any hypoglycemic activity for any of the furanoeremophilane or eremophilanolide compounds of the present invention, nor was there any suggestion in the prior art that the compounds of the present invention could be useful as antidiabetic agents.

Citation or identification of any reference in Section 2 of this application shall not be construed as an admission that such reference is available as prior art to the present invention.


3. SUMMARY OF THE INVENTION

The present invention provides novel eremophilanolides, as well as pharmaceutically acceptable salts thereof, having hypoglycemic activity, compositions comprising the novel eremophilanolides of the present invention, as well as methods for their use. In addition, the present invention provides compositions comprising furanoeremophilanes and methods for their use as hypoglycemic agents.

Particularly, the present invention provides novel eremophilanolides having the structure of compound 3:

25

30



3

35

and pharmaceutically acceptable salts thereof for use as hypoglycemic agents.

The invention further encompasses a method for using epicacalone, cacalone, compound 3, cacalol, dimaturin, pharmaceutically acceptable salts thereof or mixtures thereof as a hypoglycemic agent.

5 Still further, the invention encompasses compositions comprising epicacalone, cacalone, compound 3, cacalol, dimaturin, pharmaceutically acceptable salts thereof or mixtures thereof for use as a hypoglycemic agent in mammals. Such compositions optionally contain
10 pharmaceutically acceptable carriers or vehicles and optionally other hypoglycemic agents.

 Still further, the invention encompasses methods for reducing blood glucose in a mammal, comprising administering to a mammal in need of such blood glucose
15 reduction, an effective amount of an extract from *Psacalium spp.* in which said extract was obtained by a process which comprised:

- (a) washing plant material from *Psacalium spp.* with a non-polar organic solvent to obtain an organic
20 solution of hypoglycemically active compounds;
- (b) concentrating the organic solution to obtain an enriched mixture of hypoglycemically active compounds;
- (c) washing the enriched mixture of hypoglycemically active compounds with a biphasic mixture of
25 a polar solvent and a hydrocarbon solvent to obtain a bioactive polar solution, wherein said polar solvent and said bioactive polar solution are immiscible in said hydrocarbon solvent; and
- (d) concentrating said bioactive polar solution to
30 obtain an extract useful as a hypoglycemic agent.

 Still further, the invention encompasses methods for treatment of diabetes mellitus comprising administering to a mammal suffering from diabetes mellitus a therapeutically active amount of an extract from *Psacalium spp.* in which said
35 extract was obtained by a process which comprised:

(a) washing plant material from *Psacalium* spp. with a non-polar organic solvent to obtain an organic solution of hypoglycemically active compounds;

(b) concentrating the organic solution to obtain
5 an enriched mixture of hypoglycemically active compounds;

(c) washing the enriched mixture of hypoglycemically active compounds with a biphasic mixture of a polar solvent and a hydrocarbon solvent to obtain a bioactive polar solution, wherein said polar solvent and said
10 bioactive polar solution are immiscible in said hydrocarbon solvent; and

(d) concentrating said bioactive polar solution to obtain an extract useful as a hypoglycemic agent.

Still further, the invention includes
15 pharmaceutical compositions for use as a hypoglycemic agent in mammals, comprising a therapeutically effective amount of an extract from *Psacalium* spp. in which said extract was obtained by a process which comprised:

(a) washing plant material from *Psacalium* spp.
20 with a non-polar organic solvent to obtain an organic solution of hypoglycemically active compounds;

(b) concentrating the organic solution to obtain an enriched mixture of hypoglycemically active compounds;

(c) washing the enriched mixture of
25 hypoglycemically active compounds with a biphasic mixture of a polar solvent and a hydrocarbon solvent to obtain a bioactive polar solution, wherein said polar solvent and said bioactive polar solution are immiscible in said hydrocarbon solvent; and

(d) concentrating said bioactive polar solution to
30 obtain an extract useful as a hypoglycemic agent.

The present invention may be understood more fully by reference to the following figures, detailed description and illustrative examples which are intended to exemplify
35 non-limiting embodiments of the invention.

4. DESCRIPTION OF THE FIGURES

Fig. 1 is a bar graph showing the plasma glucose levels (mg/dl) of diabetic mice treated with varying doses of cacalol. Animals were dosed at 0 and 24 hours. All data points N=8 except for a=7, b=4 and c=3. *P<0.05; **P<0.01; ***P<0.001 (analysis of variance (ANOVA), one factor).

Fig. 2 is a bar graph showing the plasma glucose levels (mg/dl) of diabetic mice treated with epicacalone, cacalone, compound 3 and cacalol. Animals were dosed at 0 hour. All data points N=8 except for a=7. *P<0.05; **P<0.01; ***P<0.001 (ANOVA, one factor).

Fig. 3 is a bar graph showing the plasma glucose levels (mg/dl) of diabetic mice treated with dimaturin. **P<0.01; ***P<0.001 (ANOVA, one factor).


Fig. 4 is a graph showing the effects of epicacalone and cacalone on basal 2-deoxyglucose uptake in 3T3-L1 adipocytes.

Fig. 5 is a bar graph showing the effects of epicacalone and cacalone on insulin-stimulated 2-deoxyglucose uptake in 3T3-L1 adipocytes.


5. DETAILED DESCRIPTION OF THE INVENTION

5.1 EREMOPHILANOLIDE HYPOGLYCEMIC AGENTS

The novel eremophilanolides of the present invention useful as hypoglycemic agents have the structure of compound 3:




It is to be understood that the invention
5 encompasses both epimers of compound 3, namely compound 3a:



3a

20 and compound 3b:



3b

Compound 3 or epimers 3a or 3b can be obtained via
extraction from *Psacalium* spp., preferably *P. decompositum*
35 (see Section 5.2, below) or from conventional organic
synthesis using methods known to those of skill in the art.

5.2 PROCESSES FOR ISOLATING FURANOEREMOPHILANE AND EREMOPHILANOLIDE HYPOGLYCEMIC AGENTS

The furanoeremophilane and eremophilanolide sesquiterpenes useful as hypoglycemic agents can be isolated from *Psacalium* spp., preferably *P. decompositum*, using the illustrative methods described below or other standard extraction techniques known to those of ordinary skill in the art.

5.2.1 ISOLATION USING AQUEOUS AND ALCOHOLIC SOLVENT EXTRACTION

Plant material from *Psacalium* spp., preferably *P. decompositum*, is extracted with water to extract the hypoglycemically active compounds therefrom. By "plant material" is meant any part of the plant, such as leaves, flowers, roots and stems. The plant material may optionally be shredded, ground, macerated, or otherwise treated to reduce its surface area prior to extraction. The water temperature can range from 22° C to 100° C, preferably from 40° C to 60° C. Most preferably, the water temperature is 55° C. The water extraction can be run for several minutes to several days, preferably for one day.

After the extraction is complete, the aqueous mixture of plant material is filtered to remove undesired solids therefrom and to afford a filtrate containing hypoglycemically active compounds. If the temperature of the water used in the extraction is greater than room temperature, the water containing the hypoglycemically active compounds can be optionally cooled to room temperature prior to filtration. The resulting filtrate is concentrated, preferably *in vacuo*, to afford an amorphous extract.

The amorphous extract is added to a cold solution of aqueous organic alcohol so as to precipitate insoluble impurities therefrom. By "aqueous organic alcohol" is meant a solution of water and an organic alcohol such as methanol, ethanol, isopropanol, sec-butanol and the like, wherein the ratio of water to organic alcohol ranges from 5:95 to 95:5 volume/volume (v/v), preferably from 5:95 to 20:80 v/v. Most

preferably, the ratio of water to organic alcohol is from 10:90 to 20:80 v/v and the organic alcohol is isopropanol. By "cold" is meant that the temperature of the aqueous organic alcohol is below room temperature but above the
5 freezing point of the aqueous organic alcohol solution. Preferably, the temperature of the aqueous organic alcohol solution is between 0° and 10° C.

Following addition of the amorphous extract to the cold aqueous organic alcohol solution, the resulting mixture
10 is allowed to stand at a temperature below room temperature but above the freezing point of the aqueous organic alcohol solution to allow for the formation of solid impurity. The length of time necessary for formation of the solid impurity depends upon such factors as the ratio of water to organic
15 alcohol solution, the temperature of the aqueous organic alcohol solution, the percentage of solid impurity, etc. Preferably, the mixture of amorphous extract and aqueous organic alcohol is allowed to stand from 1 to 24 hours. The filtrate containing the hypoglycemically active compounds is
20 separated from the solid impurity by filtration or decantation to afford a supernatant containing the hypoglycemically active compounds. The supernatant is concentrated, preferably *in vacuo*, to afford an enriched bioactive material.

25 The enriched bioactive material is diluted with an organic solvent capable of dissolving the enriched bioactive material and the hypoglycemically active compounds therein and washed with an aqueous acidic solution to remove nitrogen-containing impurities, including but not limited to
30 undesired alkaloids, therefrom. Suitable organic solvents are those which are immiscible in water and include ethyl acetate, diethyl ether, hexane, chloroform, carbon tetrachloride and preferably, dichloromethane (DCM). Suitable aqueous acidic solutions are dilute solutions of
35 water and acids such as hydrochloric, nitric, sulfuric, acetic and citric. Preferably, the aqueous acidic solution is an aqueous solution of hydrochloric acid, most preferably

1N HCl. After the organic solution is washed with the aqueous acidic solution, the organic solution free from alkaloid impurities and containing the hypoglycemicall
active compounds is concentrated, preferably *in vacuo*, to
5 afford a crude mixture of hypoglycemicall active compounds epicacalone, cacalone and compound 3.

The crude mixture of hypoglycemicall active compounds can be purified by recrystallization or chromatography, preferably high-performance liquid
10 chromatography, to afford pure hypoglycemicall active compounds. When high-performance liquid chromatography is used to separate the crude mixture into fractions containing pure hypoglycemicall active compounds, the eluent solution is generally a mixture of water and a polar organic solvent
15 miscible with water. Preferably, the eluent solution is a mixture of acetonitrile and water. Optionally, the resulting fractions may be repurified using high-performance liquid chromatography to obtain fractions of higher purity, using the same or preferably a slower elution flow rate.

20

5.2.2 ISOLATION USING NON-POLAR ORGANIC SOLVENT EXTRACTION

In a preferred embodiment of the invention, plant material from *Psacalium spp.*, preferably *P. decompositum*, is
25 washed with a non-polar organic solvent to extract hypoglycemicall active furanoeremophilane or eremophilanolide compounds therefrom while leaving behind undesired alkaloid impurities in the plant material. The plant material may optionally be shredded, ground, macerated,
30 or otherwise treated to reduce its surface area prior to washing. Suitable non-polar organic solvents useful in this regard include dichloromethane and mixtures of diethyl ether and hexane. When mixtures of diethyl ether and hexane are used, the ratio of diethyl ether to hexane is preferably 1:2.
35 The preferred non-polar organic solvent is dichloromethane. After washing the plant material, the non-polar organic solvent containing the hypoglycemicall active compounds is

concentrated, optionally *in vacuo*, to afford an extract enriched in hypoglycemicly active compounds.

The enriched extract is then diluted with a polar solvent and washed with a hydrocarbon solvent so as to remove
5 non-polar organic impurities therefrom. Useful polar solvents include, but are not limited to, methanol, ethanol, isopropanol, acetone, 2-butanone, ethyl acetate, tetrahydrofuran, dimethylformamide, N-methylpyrrolidinone, dimethyl sulfoxide, water and mixtures thereof. It is
10 important that the polar solvent be immiscible in the hydrocarbon solvent so as to form an effective biphasic partitioning system. Useful hydrocarbon solvents include benzene, toluene, pentane, hexane, heptane, higher ($> C_7$) alkanes and other hydrocarbon solvents, such as petroleum
15 ether, immiscible in the polar solvent. Preferably, the hydrocarbon solvent is petroleum ether and the polar solvent is a mixture of ethanol and water. Most preferably, the polar solvent is 10% aqueous ethanol. After washing the enriched extract, the polar solvent phase is separated and
20 then concentrated, optionally *in vacuo*, to afford a residue of bioactive material containing cacalol, dimaturin, compound 3, epicacalone and cacalone.

The bioactive material is purified by recrystallization or chromatography, preferably vacuum flash
25 chromatography. When vacuum flash chromatography is used, the bioactive material is preferably pre-adsorbed onto silica gel which is then added to the top of a column of clean silica gel and eluted with standard organic solvent systems, preferably ethyl acetate/hexane. Preferably, the bioactive
30 material is pre-adsorbed onto silica gel by dissolving the bioactive material in an organic solvent such as dichloromethane, adding silica gel to the dichloromethane solution of the hypoglycemicly active compounds to afford a silica gel slurry and drying the silica gel, preferably *in*
35 *vacuo*. The fractions obtained from the vacuum flash chromatography are concentrated, optionally *in vacuo*, to afford purified hypoglycemicly active compounds.

Preferably, the concentrated fractions are repurified using recrystallization or chromatography to afford pure cacalol, dimaturin, compound 3, epicacalone and cacalone.

Repurification may be repeated several times or until the 5 desired degree of compound purity is obtained.

5.3 METHODS FOR USE OF HYPOGLYCEMICALLY ACTIVE FURANOEREMOPHILANE AND EREMOPHILANOLIDE COMPOUNDS

Due to the potent hypoglycemic activity of the
10 furanoeremophilane and eremophilanolide sesquiterpenes of the present invention, the furanoeremophilane or eremophilanolide compounds are advantageously useful in veterinary and human medicine for therapeutic treatment of diabetes mellitus. Additionally, the furanoeremophilane or eremophilanolide
15 compounds can be advantageously used as hypoglycemic agents to reduce the blood glucose level in situations of acute stress such as experienced by animals or patients with hyperthermia, trauma, sepsis, and burns and undergoing general anesthesia. Hyperglycemia sometimes associated with
20 severe head injury, cerebral thrombosis, encephalitis and heat stroke can also be therapeutically treated with these compounds. Additionally, the furanoeremophilane or eremophilanolide compounds are useful as hypoglycemic agents for rare congenital metabolic glycogen storage disease
25 associated with hyperglycemia.

Although the present inventors do not wish to be limited to any particular mechanism of action to explain the hypoglycemic activity of the furanoeremophilane or eremophilanolide compounds of the present invention, it is
30 envisaged that they may advantageously be useful for treatment of both insulin-dependent or type I diabetes (formerly termed juvenile-onset or ketosis-prone diabetes) and non-insulin-dependent or type II diabetes (formerly termed adult-onset, maturity-onset or nonketotic diabetes).

35 When administered to a mammal for veterinary use or to a human for clinical use, the furanoeremophilane or eremophilanolide compounds can be used alone, or may be

combined with any physiologically acceptable carrier such as water, an aqueous solution, normal saline, or other physiologically acceptable excipient. In general, the dosage would range from about 10-1000 mg/kg/day, preferably about 5 10-250 mg/kg/day.

The furanoeremophilane or eremophilanolide compounds can be administered by a number of routes, including, but not limited to: orally, injection including, but not limited to intravenously, intraperitoneally, 10 subcutaneously, intramuscularly, etc. The preferred route of administration is oral. Additionally, the furanoeremophilane or eremophilanolide compounds can be administered in conjunction with another hypoglycemic agent including such as insulin; a biguanide such as metformin or buformin; a 15 sulfonylurea such as acetohexamide, chlorpropamide, tolazamide, tolbutamide, glyburide, glypizide or glyclazide; a thiazolidinedione such as troglitazone; an α -glycosidase inhibitor such as acarbose or miglatol; or a β_3 -adrenoceptor agonist such as CL-316, 243, etc.

20 The furanoeremophilane or eremophilanolide compounds of the present invention can optionally be administered in an effective amount as pharmaceutically acceptable phenolate salts using counter ions such as sodium, potassium, lithium, calcium, magnesium, zinc and iron.

25 In addition, the furanoeremophilane or eremophilanolide compounds or pharmaceutically acceptable salts thereof can be used for research purposes, for example, to investigate the mechanism and activity of hypoglycemic agents.

30

5.4 METHODS FOR ISOLATING AND USING EXTRACTS OF PSACALIUM SPP.

Extracts of *Psacalium* spp. prepared using the methods described in Section 3, above, have hypoglycemic 35 activity.

Due to the potent hypoglycemic activity of the extracts of *Psacalium* spp. of the present invention, the

extracts of *Pscadium spp.* are advantageously useful in veterinary and human medicine for therapeutic treatment of diabetes mellitus. Additionally, the extracts of *Pscadium spp.* can be advantageously used as hypoglycemic agents to
5 reduce the blood glucose level in situations of acute stress such as experienced by animals or patients with hyperthermia, trauma, sepsis, and burns and undergoing general anesthesia. Hyperglycemia sometimes associated with severe head injury, cerebral thrombosis, encephalitis and heat stroke can also be
10 therapeutically treated with these compounds. Additionally, the extracts of *Pscadium spp.* are useful as hypoglycemic agents for rare congenital metabolic glycogen storage disease associated with hyperglycemia.

Although the present inventors do not wish to be
15 limited to any particular mechanism of action to explain the hypoglycemic activity of the extracts of *Pscadium spp.* of the present invention, it is envisaged that they may advantageously be useful for treatment of both insulin-dependent or type I diabetes (formerly termed juvenile-onset
20 or ketosis-prone diabetes) and non-insulin-dependent or type II diabetes (formerly termed adult-onset, maturity-onset or nonketotic diabetes).

When administered to a mammal for veterinary use or to a human for clinical use, the extracts of *Pscadium spp.*
25 can be used alone, or may be combined with any physiologically acceptable carrier such as water, an aqueous solution, normal saline, or other physiologically acceptable excipient. In general, the dosage would range from about 10-1000 mg/kg/day, preferably about 10-250 mg/kg/day.

30 The extracts of *Pscadium spp.* can be administered by a number of routes, including, but not limited to: orally, injection including, but not limited to intravenously, intraperitoneally, subcutaneously, intramuscularly, etc. The preferred route of administration
35 is oral. Additionally, the extracts of *Pscadium spp.* can be administered in conjunction with another hypoglycemic agent including such as insulin; a biguanide such as metformin or

buformin; a sulfonylurea such as acetohexamide, chlorpropamide, tolazamide, tolbutamide, glyburide, glypizide or glyclazide; a thiazolidinedione such as troglitazone; an α -glycosidase inhibitor such as acarbose or miglatol; or a β_3 -
5 adrenoceptor agonist such as CL-316, 243, etc.

The extracts of *Pscadium* spp. of the present invention can optionally be administered in an effective amount as pharmaceutically acceptable phenolate salts using counter ions such as sodium, potassium, lithium, calcium,
10 magnesium, zinc and iron.

In addition, the extracts of *Pscadium* spp. or pharmaceutically acceptable salts thereof can be used for research purposes, for example, to investigate the mechanism and activity of hypoglycemic agents.

15 The following series of Examples are presented by way of illustration and not by way of limitation on the scope of the invention.

20 6. EXAMPLE: ISOLATION AND CHARACTERIZATION OF FURANOEREMOPHILANE AND EREMOPHILANOLIDE SESQUITERPENES

6.1 MATERIALS AND METHODS

Analytical high performance liquid chromatography (HPLC) was performed on a Hitachi Model D-6500 Chromatography Data Station equipped with a L-6200A pump, AS-2000
25 autosampler, L-4500 A diode array detector and a Sedex 55 light scattering detector connected in parallel. Columns used in analytical HPLC were an ODS-AQ (YMC Inc.), 4 x 50 mm (3 μ m), and phenyl (YMC Inc.), 4 x 50 mm (3 μ m).
Semi-preparative HPLC was performed on a Hitachi Model D-
30 6500 Chromatography Data Station equipped with a Waters 600 pump controller, L-4500 A diode array detector, and a L-5200 Hitachi fraction collector. Columns used in semi-preparative HPLC were a PRP-1 (Hamilton), 20 x 250 mm (10 μ m) column, ODS-AQ (YMC Inc.), 20 x 150 mm (5 μ m) equipped with a
35 20 x 50 mm guard column, and a phenyl (YMC Inc.), 20 x 250 mm (5 μ m) column. Preparative HPLC chromatography was performed with a Rainin Dynamax HPLC system equipped with a Dynamax


Diode Array Detector (Model PDA-1), solvent delivery pumps (Model SD-1), and interfaced with Dynamax PC HPLC Data System. Chromatographic columns used were a Hamilton PRP-1, 50 x 250 mm or Primesphere C18 HC (10 μ m) 50 x 250 mm with a pre-column 50 x 30 mm (both columns obtained from Phenomenex, Torrance, CA). All chromatographic runs were performed at ambient temperature. HPLC grade or ACS grade solvents were used without further purification.

Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Unity Plus 400 or a Varian Unity 400 spectrometer. All NMR spectra of compounds were recorded in deuterated chloroform. One and two-dimensional NMR experiments, including Distortionless Enhancement Polarization Transfer (DEPT), H-H Correlation Spectroscopy (COSY), Heteronuclear Multiple Quantum Correlation (HMQC), Heteronuclear Multiple Bond Correlation (HMBC), long-range Heteronuclear Chemical Shift Correlation (HETCOR), and Rotating-frame Overhauser Enhancement Spectroscopy (ROESY), provided molecular structure information. Mass spectra (MS) were recorded on a Kratos MS-50 in high resolution power electron impact scanning mode, 70 ev. Resolution was set to 2000, scanning rate 10 sec/decay, temperature gradient from 50° to 300° C increased at a rate of 50°/min. IR spectra were recorded on a Perkin-Elmer 1600 Series FTIR. UV spectra were recorded on a Perkin-Elmer Lambda 2 UV/VIS spectrometer or taken directly from the Hitachi diode-array UV detector on the HPLC system. Melting points were measured on a Buchi 535 apparatus and are uncorrected.

6.2 ISOLATION OF EPICACALONE, CACALONE AND COMPOUND 3 USING AN AQUEOUS AND ALCOHOLIC SOLVENT EXTRACTION

In a general scheme for the isolation of bioactive compounds from *P. decompositum*, 500 g of the shredded and ground roots of *P. decompositum* were steeped in water at a temperature of 55° C for 24 hrs. The liquid, upon cooling, was separated from the solids by filtration. The water extract was concentrated by removal of water *in vacuo* to

yield 77.4 g of an amorphous extract. A 15.1 g portion of this extract was treated with 90 mL of cold water followed by the addition of 600 mL of isopropyl alcohol. The mixture was left to stand at 4° C for 12 hrs. and the solids removed by
5 decantation. Upon separation, the supernatant was concentrated *in vacuo* to yield 6.45 g of an enriched bioactive mixture. A 5.53 g portion of the enriched bioactive material was then partitioned between 75 mL of dichloromethane and 55 mL of 1 N hydrochloric acid. The
10 aqueous acidic phase was extracted three times with 75 mL of dichloromethane. The dichloromethane extracts were combined and washed three times with 50 mL of 0.5 N hydrochloric acid, and then washed twice with 100 mL of water until the aqueous phase was pH 7. The resultant dichloromethane fraction was
15 now highly enriched in furanoeremophilane-type compounds and devoid of alkaloids. The fraction devoid of alkaloids was concentrated to dryness *in vacuo* to yield 163 mg. A representation of this extraction is shown in Scheme 1. This procedure was repeated in order to produce additional amounts
20 of the enriched fraction containing the furanoeremophilane-type compounds. A 132 mg portion of the furanoeremophilane-type enriched fraction was further purified by high performance liquid chromatography using a PRP-1 (Hamilton) 20 x 250 mm (10 μ m) column, eluting with a
25 linear gradient of acetonitrile and water. A flow rate of 16 mL/min was used and detection of eluting peaks was performed using an UV detector at 228 nm. The chromatogram displayed one peak eluting at approximately 14.3 min. This peak was collected to yield 34 mg of enriched bioactive material.
30 Further fractionation was accomplished using high performance liquid chromatography using an ODS-AQ (YMC Inc.) 20 x 200 (5 μ m) column, eluting with a linear gradient of acetonitrile-water, at a flow rate of 12 mL/min. Three components were isolated and identified as epicacalone (15.2
35 mg), cacalone (0.6 mg), and compound 3 (2.3 mg). Compound 3 is a 1:1 mixture of two new epimeric eremophilanolide sesquiterpenes 3a and 3b.



Scheme 1. Isolation of furanoeremophilane-type sesquiterpenes from the aqueous extract of *P. decompositum*.

6.3 ISOLATION OF CACALOL, DIMATURIN, COMPOUND 3, EPICACALONE AND CACALONE USING A NON-POLAR ORGANIC SOLVENT EXTRACTION

Non-polar organic solvents, such as dichloromethane or mixtures of diethyl ether and hexane (1:2), can be used in the extraction process and were found to extract the furanoeremophilane-type sesquiterpenes but not pyrrolizidine alkaloids from *P. decompositum*. Isolation of gram quantities of epicacalone, cacalone and compound 3 involved using dichloromethane as the extraction solvent as shown in Scheme 2. Shredded and ground root material (5 kg) was extracted

with dichloromethane for six hours at room temperature yielding 321.4 g of extract after evaporation of the dichloromethane solvent. The extract was partitioned between 10% aqueous ethanol and petroleum ether. The aqueous ethanol
5 phase yielded 149.3 g of bioactive material after evaporation. The bioactive material was fractionated by vacuum flash chromatography using the following protocol: The bioactive material was dissolved in dichloromethane and 1.5 L of silica gel (70-230 mesh, 60 A) was added. The
10 slurry was then dried by rotary evaporation to produce a silica gel coated with the bioactive material. The coated silica gel was added on top of 1 L of clean silica gel in a 3 L (15.5 cm i.d.) vacuum funnel for a final bed size of 15.5 x 12 cm. The column was eluted with hexane and ethyl acetate.
15 Fraction 1, eluting with hexane/ethyl acetate (85:15), contained 38.5 g of enriched material. This material was recrystallized from petroleum ether to afford 14.8 g of cacalol. Fraction 2 was obtained from the silica gel column by eluting with hexane/ethyl acetate 85/15 to 80/20. After
20 removal of solvent this fraction gave 8.97 g. Recrystallization from ethyl acetate yielded dimaturin (0.14 g). Upon further elution with hexane/ethyl acetate (80/20) fraction 3 was obtained. This fraction (15.2 g) was purified by HPLC on a PRP-1 (Hamilton) 50 x 250 mm column eluting with
25 a linear gradient of acetonitrile-water. In this manner compound 3 (1.06 g) was obtained and was a mixture of 1:1 epimers 3a and 3b. Further elution on the PRP-1 column resulted in an enriched fraction containing a mixture (~1:1:1) of epicacalone, cacalone and compound 3 (5.56 g).
30 The mixture was further chromatographed on a Primesphere ODS HC 10 μ , 50 x 250 mm column (Phenomenex) equipped with a precolumn (50 x 30 mm) under isocratic conditions (70/30 acetonitrile/water, 50 mL/min, 15 min.) to yield 1.43 g of epicacalone and 3.24 g of a mixture of cacalone and compound
35 3. The final separation of cacalone from compound 3 was carried out by re-chromatographing the cacalone/compound 3 mixture (8 x 150 mg) on the Primesphere ODS column with

isocratic conditions (60/40 acetonitrile/water, 50mL/min, run time: 25 min) to give pure cacalone (412 mg) and compound 3 (350 mg). The two epimers of compound 3 were separated by HPLC with a semi-preparative phenyl (YMC Inc.) 20 x 250 mm (5 μ m) column with a linear gradient of methanol-water (15 mL/min, 11-12 min).

10


15

20

25

30

35



Scheme 2. Isolation of furanoeremophilane-type sesquiterpenes from a dichloromethane extract of *P. decompositum*.

6.4 STRUCTURE ELUCIDATION OF CACALOL, DIMATURIN, COMPOUND 3, EPICACALONE AND CACALONE

Epicacalone (1) was obtained as a white solid, m.p. 128-130°, $[\alpha]_D + 81^\circ$ (c 1.00). The IR spectrum (thin film on KBr) indicated the presence of the hydroxy (3413 cm^{-1}) and also showed bands at 2934 and 1652 cm^{-1} . The HPLC UV diode-array spectrum displayed two absorption maxima at 257 and 325 nm in acetonitrile-water (~1:1). The molecular formula, $\text{C}_{15}\text{H}_{18}\text{O}_3$, was determined by high resolution electron impact mass spectrometry (HREIMS) m/z 246.1254 (M^+ , Δ 0.2 mmu of calc.) and a DEPT ^{13}C NMR spectrum. Comparison of the reported chemical shifts for cacalone (F. Yuste, E. Diaz, F. Walls, K. Jankowski, J. Org. Chem., 1976, 41, 4103-4106; K. Jankowski, E. Diaz, F. Yuste, Proc. Indian Acad. Sci. (Chem. Sci.), 1984, 93, 1317-1321) to those assigned in epicacalone indicated similar shifts were observed overall, however several of the assignments were not in agreement. Tables 1 and 2 list the assigned ^{13}C and ^1H chemical shifts for epicacalone and are based on one and two-dimensional NMR experiments known to those skilled in the art of structure elucidation and include Distortionless Enhancement Polarization Transfer (DEPT), H-H Correlation Spectroscopy (COSY), Heteronuclear Multiple Quantum Correlation (HMQC), Heteronuclear Multiple Bond Correlation (HMBC), long-range Heteronuclear Chemical Shift Correlation (HETCOR) experiments.

The stereochemistry in epicacalone was assigned as 4- β -hydroxy-5- β -methyl based on the comparison of the CH_3 -5 proton chemical shift (1.31 ppm, lit. value 1.31 ppm (K. Omura, M. Nakanishi, K. Takai, K. Naya, Chem. Letters, 1978, 1257-1260) and melting point of epicacalone isolated herein (128-130°) with the reported values for epicacalone (lit. m.p. 129-131° (K. Omura, M. Nakanishi, K. Takai, K. Naya, Chem. Letters, 1978, 1257-1260)). The absolute stereochemistry at C-5 in cacalone was previously established as S (M. Terabe, M. Tada, T. Takahashi, Bull. Chem. Soc. Jpn., 1978, 51, 661-662). One discrepancy was noted between


the $[\alpha]_D$ values reported for epicacalone (+95°) and cacalone (+87°) with those measured for epicacalone (+81°) and cacalone (+95°) obtained from this isolation process. The values appear to be reversed. In order to ensure that the stereochemistry for epicacalone obtained from extraction of *P. decompositum* was the same as the epicacalone reported in the literature, ROESY experiments were performed with both epicacalone and cacalone obtained herein then compared to calculated distances of key protons from molecular modeling results with literature-reported epicacalone and cacalone. A ROESY correlation was observed between CH₃-3 to CH₃-5 in epicacalone while absent in cacalone. The relative calculated distances between protons from CH₃-3 to CH₃-5 in epicacalone and cacalone predicts these methyls to be closer in epicacalone (4.9 vs. 5.8 Å) and separated by too great a distance in cacalone for an nOe effect. In addition, a strong ROESY correlation was observed between CH₃-4 and CH₃-5 in cacalone while a weak ROESY correlation was observed in epicacalone. This correlation reflects the closer distance between protons CH₃-4 to CH₃-5 in cacalone (2.2 Å). The ROESY correlations and modeling results support the assigned stereochemistry of **1** as epicacalone and **2** as cacalone.

25	Calculated distances (Å)	Cacalone	Epicacalone
	CH ₃ -3 - CH ₃ -5	4.9	5.8
	CH ₃ -3 - CH ₃ -4	2.4	2.4
	CH ₃ -4 - CH ₃ -5	4.0	2.2

30 The assigned stereochemistry for epicacalone including the prochirality of H-6/H-6' and H-8/H-8' are shown below.

35

5




1

10

Cacalone (2) was obtained as a white solid, m.p. 139-141°, $[\alpha]_D +95^\circ$ (c 1.00). Spectra obtained for cacalone were very similar to epicacalone. The IR spectrum (thin film on KBr) indicated the presence of the hydroxy group (3390 cm^{-1}) and also showed bands at 2937 and 1652 cm^{-1} . The HPLC UV diode-array spectrum displayed two absorption maxima at 253 and 326 nm in acetonitrile-water (~1:1). The molecular formula, $\text{C}_{15}\text{H}_{18}\text{O}_3$, was determined by HREIMS m/z 246.1251 (M^+ , Δ 0.5 mmu of calc.) and a DEPT ^{13}C NMR spectrum. COSY, HMQC and HMBC experiments were used to completely assign the ^{13}C and ^1H chemical shifts in cacalone which are listed in Tables 1 and 2. The stereochemistry at C-4 in cacalone was assigned as 4- α -hydroxy-5- β -methyl based on the comparison of the CH_3 -5 proton chemical shift (1.26 ppm, lit. value 1.24 ppm (K. Omura, M. Nakanishi, K. Takai, K. Naya, Chem. Letters, 1978, 1257-1260)) and melting point of SP-67002 (139-141°) with the reported values (lit. m.p. 139-141°) (K. Omura, M. Nakanishi, K. Takai, K. Naya, Chem. Letters, 1978, 1257-1260).

30




35

5


2

10 Compound 3 was obtained as a 1:1 mixture of two
epimers and identified as a new eremophilanolide
sesquiterpene. A single peak was displayed by HPLC with an
ODS-AQ (YMC) column; however, two peaks in a 1:1 ratio were
15 observed with a phenyl column utilizing a methanol-water
gradient. A doubling of peaks was also observed in carbon
and proton NMR spectra suggesting the presence of a 1:1
mixture. The IR spectrum (thin film on KBr) indicated the
presence of the hydroxy (3374 cm^{-1}) and lactone (1798 cm^{-1}) and
also showed bands at 2930 and 1635 cm^{-1} . The UV displayed two
20 absorption maxima at 201 nm ($\log \epsilon\ 4.27$) and 295 nm ($\log \epsilon\ 3.37$).
The molecular formula, $\text{C}_{15}\text{H}_{18}\text{O}_4$, was determined by
HREIMS $m/z\ 262.1204$ (M^+ , $\Delta\ 0.4\text{ mmu}$ of calc.) and a DEPT ^{13}C
NMR spectrum. Tables 1 and 2 list the assigned ^{13}C and ^1H
chemical shifts for compound 3 and are based on two-
25 dimensional NMR experiments, including COSY, HMQC, HMBC, and
long-range HETCOR experiments. The two epimers of compound 3
were separated by HPLC with a semi-preparative phenyl (YMC
Inc.) $20 \times 250\text{ mm}$ ($5\ \mu\text{m}$) column with a linear gradient of
methanol-water (15 mL/min , 11.2 min , 12.0 min). The
30 stereochemistry at C-3 is described for 3a and 3b below.

35




10 Compound **3a** was obtained as a white solid, $[\alpha]_D +35^\circ$ (c 0.462). The molecular formula, $C_{15}H_{18}O_4$, was determined by HREIMS m/z 262.1207 (M^+ , Δ 0.2 mmu of calc.) and a DEPT NMR spectrum. The carbon and proton chemical shifts in Tables 1 and 2 were assigned by analysis of COSY, HMQC, HMBC and long-
 15 range HETCOR experiments. The stereochemistry at C-3 and C-5 was assigned as 3β -hydroxy- 3α -methyl and 5β -methyl and was based on ROESY and proton NMR spectra.



Compound **3b** was obtained as a white solid, $[\alpha]_D -18^\circ$ (c 0.588). The molecular formula, $C_{15}H_{18}O_4$, was determined by HREIMS m/z 262.1216 (M^+ , Δ 1.1 mmu of calc.) and a DEPT NMR spectrum. The carbon and proton chemical shifts in Tables 1 and 2 were assigned by analysis of COSY, HMQC, HMBC and long-
 30 range HETCOR experiments. The stereochemistry at C-3 and C-5 was assigned as 3α -hydroxy- 3β -methyl and 5β -methyl and was based on ROESY and proton NMR spectra.

5

3b




10

Cacalol (4) was obtained as a yellow crystalline solid after recrystallization from petroleum ether. The IR spectrum (thin film on KBr) indicated the presence of a hydroxy group (3057 cm^{-1}) and also exhibited bands at 2927 cm^{-1} and a weak transition at 1629 cm^{-1} . The HPLC UV diode-array spectrum displayed two absorption maxima at 257 and 221 nm in acetonitrile-water (~1:1). The molecular formula, $\text{C}_{15}\text{H}_{18}\text{O}_2$, was determined by HREIMS m/z 230.1309 (M^+ , Δ 0.2 mmu of calc.) and a DEPT NMR spectrum. The overall ^{13}C shifts were similar in magnitude to reported values, however several assignments differ. COSY, HMQC, and HMBC experiments were used to accurately assign the ^{13}C and ^1H chemical shifts in cacalol which are listed in Tables 1 and 2, respectively.

25


30

35



Dimaturin (5) (J. Correa, J. Romo, Tetrahedron, 15 1966, 22, 685-691) was obtained as a yellow solid after recrystallization in ethyl acetate or acetone, m.p. 202-204°C (lit. m.p. 201-203°). A FAB MS spectrum exhibited a $[M+1]^+$ peak at 523, and is consistent with the molecular formula $C_{32}H_{26}O_7$. Analysis of the DEPT NMR spectrum indicated that 20 there were nine unsaturated CH groups including one aldehyde, four CH_3 's consisting of two methoxy's and two methyls attached to an aromatic ring system, one hemiacetal, and two $O-CH_2-$ groups. Comparison of the proton NMR with one reported for dimaturin, along with the DEPT data, confirmed the 25 structure of dimaturin. ^{13}C NMR (CDC13, 100MHz, δ in ppm, multiplicity): 193.4 (d), 148.8 (s), 147.8 (d), 142.4 (s), 141.7 (s), 138.8 (s), 137.6 (d), 133.4 (s), 130.7 (s), 130.3 (s), 130.1 (d), 128.2 (d), 128.0 (s), 127.8 (s), 126.0 (s), 125.2 (s), 124.5 (d), 123.3 (d), 121.7 (s), 30 121.5 (d), 121.2 (s), 120.9 (d), 118.5 (s), 116.7 (s), 114.2 (s), 95.7 (d), 63.0 (t), 61.0 (q), 60.2 (q), 54.5 (t), 26.6 (q), 23.3 (q). 1H NMR (CDC $_{13}$, 400 MHz, δ in ppm, multiplicity, J (Hz), number of hydrogens): 2.72 (s, 3H), 2.87 (s, 3H), 4.39 (s, 3H), 4.24 (s, 3H), 4.97 (d, 14, 1H), 35 5.08 (dd, 14, 1.2, 1H), 5.14 (dd, 14, 2.0, 1H), 5.34 (dd, 14, 1.6, 1H), 6.80 (s, 1H), 7.25 (m, 2H), 7.35 (m, 2H), 7.41

(m, 1H), 7.78 (m, 1H), 8.24 (m, 1H), 8.31 (dd, 8.4, 0.8, 1H),
10.9 (s, 1H).



25

5

30

35

Table 1. ¹³C Chemical Shift Values for Epicalalone, Cacalone, Compound 3, Cacalol 4, Compound 3a and Compound 3b

Carbon #	epicalalone	cacalone	Compound 3	cacalol	Compound 3a	Compound 3b
2	144.3 (d, J _{C-H} = 202 Hz)	144.3 d	178.3 - 178.0 s	140.7 d	178.7 s	178.0 s
3	120.2 s	120.3 s	74.6 - 74.4 s	117.0 s	74.4 s	74.5 s
3a	140.4 s	140.4 s	124.6 - 124.5 s	126.0 s	124.7 s	124.5 s
4	72.2 s	70.5 s	125.0 - 124.9 s	120.1 s	124.9 s	124.8 s
4a	161.6 s	161.6 s	138.5 - 138.3 s	135.5 s	138.2 s	138.5 s
5	28.5 d	27.2 d	28.7 - 28.6 d	28.9 d	28.7 d	28.6 d
6	30.2 t	30.1 t	29.6 - 29.4 t	30.0 t	29.6 t	29.4 t
7	16.0 t	15.6 t	16.2 - 16.1 t	16.6 t	16.2 t	16.1 t
8	21.6 t	20.7 t	23.0 - 23.2 t	22.9 t	23.2 t	23.0 t
8a	130.6 s	130.6 s	126.65 - 126.59 s	118.7 s	126.6 s	126.6 s
9	175.0 s	175.1 s	135.4 - 135.1 s	136.2 s	134.9 s	135.5 s
9a	145.1 s	145.2 s	137.0 - 136.8 s	142.1 s	137.0 s	136.8 s
CH ₃ -3	8.8 q	9.0 q	24.6 - 24.1 q	11.2 q	24.0 q	24.6 q
CH ₃ -4	27.2 q	25.7 q	12.64 - 12.61 q	13.7 q	12.6 q	12.6 q
CH ₃ -5	21.3 q	20.7 q	20.75 - 20.72 q	21.3 q	20.7 q	20.8 q

5

10

15

20

25

30

Table 2. ¹H Chemical Shift Values for Epicalalone, Cacalone, Compound 3, Cacalol, Compound 3a and Compound 3b.

Proton #	epicalalone	cacalone	Compound 3	cacalol	Compound 3a	Compound 3b
2	7.34 (1H, q, 1.2)	7.31 (1H, m)		7.27 (1H, s)		
5	2.87 (1H, m)	3.12 (1H, m)	3.04 (2H, m)	3.28 (1H, m)	2.95 (1H, m)	3.01 (1H, m)
6	1.58 (1H, dddd, 12, 12, 4, 4)	1.47 (1H, dddd, 13, 13, 4, 4)	1.6 (2H, m)	1.84 (2H, m)	1.52 (1H, m)	1.7 (2H, m)
6'	1.70 (1H, m)	1.68 (1H, m)	1.76 (2H, m)		1.7 (1H, m) ²	
7	1.75-1.8 (2H, m)	1.72 (1H, m)	1.8 (4H, m)	1.9 (2H, m)	1.7 (2H, m) ²	1.77 (2H, m)
7'		1.83 (1H, m)				
8	2.33 (1H, ddd, 18, ~9, ~9)	2.35 (1H, dd, 19.6, 8.8) ¹	2.49 (1H, broad, dd) 2.34 (1H, m)	2.68 (1H, ddd, 18, 11.2, 6.8)	2.24 (1H, dd ² , 18, 8.8) ³	2.45 (1H, ddd, 18, 10, 8)
8'	2.54 (1H, ddd, 18, 6.8, 2.4)	2.54 (1H, ddd, 19, 8.4, 2.8)	2.84/2.8 (2H, m)	3.04 (1H, ddd, 17.2, 5.2, 1.2)	2.75 (1H, broad d, 18)	2.83 (1H, broad dd, 18, 6)
CH ₃ -3	2.23 (3H, d, 1.2)	2.23 (3H, d, 1.2)	1.73 (3H, s)	2.42 (3H, s)	1.67 (3H, s)	1.69 (3H, s)
CH ₃ -4	1.67 (3H, s)	1.68 (3H, s)	1.74 (3H, s) 2.334 (3H, s)	2.56 (3H, s)	2.28 (3H, s)	2.29 (3H, s)
CH ₃ -5	1.31 (3H, d, 7.2)		2.326 (3H, s) 1.12 (3H, d, 7.2) 1.14 (3H, d, 7.2)	1.24 (3H, d, 7.2)	1.05 (3H, d, 7.2)	1.10 (3H, d, 6.8)

¹ Slight overlap between H-8 and H-8', multiplicity may be ddd as in epicacalone² Overlap with H-6 and H-7³ Slight overlap with CH₃-4, multiplicity could be ddd.

7. EXAMPLE: REDUCTION OF PLASMA GLUCOSE

7.1 REDUCTION OF PLASMA GLUCOSE WITH CACALOL

This example illustrates the effectiveness of cacalol in reducing plasma glucose levels in obese diabetic *ob/ob* mice, i.e., an art-recognized model of non-insulin dependent diabetes mellitus (NIDDM) useful in predicting hypoglycemic activity in mammals, including humans.

7.1.1 MATERIALS AND METHODS

Genetically-altered obese diabetic mice (designated C57BL/6J-*ob/ob*) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA), and served as experimental animals. Male animals between the ages of 8-9 weeks were employed in the studies described herein. Animals were housed (4 mice/cage) under standard laboratory conditions at 22° C and 50% relative humidity, and were maintained on a diet of Purina rodent chow and water *ad libitum*. Prior to treatment, blood was collected from the tail vein of each animal. Mice that had plasma glucose levels between 250 and 500 mg/dL were used. Each treatment group consisted of eight mice that were distributed so that the mean glucose levels were equivalent in each group at the start of the study. Diabetic *ob/ob* mice were dosed orally by gavage once each day for two days with either vehicle, cacalol, administered at 125 mg (544 μ mol), 250 mg (1088 μ mol), or 500 mg (2176 μ mol/kg/day), or metformin [250 mg (1510 μ mol)/kg/day]. Compounds were delivered in a liquid vehicle containing 0.25% (w/v) carboxymethylcellulose, 1% (v/v) Tween 60, and up to 10% (v/v) dimethyl sulfoxide (DMSO) in a volume of 10 ml/kg. Blood was sampled from the tail vein three hours post-dosing, and analyzed for plasma glucose levels. Individual body weights and mean food consumption (each cage) were also measured after 24 h. Cacalol was purified as described in Section 6.3, above. Metformin (1,1-dimethylbiguanide) was purchased from Sigma Chemical Co. (St. Louis, MO, USA; catalog# D-5035). Plasma glucose levels were determined colorimetrically using glucose oxidase (Sigma Chemical Co.;

Sigma catalog# 315). Significant differences between groups (comparing drug-treated to vehicle-treated) were evaluated using analysis of variance and Fisher's post-hoc test.

5

7.1.2 RESULTS

As illustrated in Fig. 1, metformin (reference compound) and all three dose-levels of cacalol resulted in significant reductions in plasma glucose at both dose intervals with changes in 68, 77, and 94 mg/dL in the 544 μ mol, 1088 μ mol, or 2176 μ mol/kg groups after the second dose ($P < 0.0243$, 0.007, and 0.003, respectively). The antihyperglycemic effects of cacalol at 544 μ mol/kg and 1088 μ mol/kg occurred in the absence of any measurable effect on food intake or body weight (Table 3). When given at 2176 μ mol/kg, cacalol did result in a reduction in food intake. Metformin (1510 μ mol/kg) lowered plasma glucose by approximately 108 mg/dl 3 hours after the initial dose ($P < 0.0001$), and by approximately 80 mg/dl 3 hours after the second dose ($P < 0.0001$). These data indicate that cacalol is an effective oral anti-hyperglycemic agent in a rodent model of insulin resistance, obesity, and NIDDM.

Table 3

Effect of Cacalol on Body Weight and Food Consumption

TREATMENT	Body weight (g/mouse) (mean \pm sem)	Body weight (g/mouse) (mean \pm sem)	Food Intake (g/mouse)
	0 h	24 hr	0-24 h
Vehicle	45.1 \pm 0.9	45.2 \pm 1.0	5.3
Metformin 250 mg/kg	47.2 \pm 0.9	47.5 \pm 0.9	5.0
Cacalol 125 mg/kg	49.7 \pm 1.2	49.5 \pm 1.2	5.2
Cacalol 250 mg/kg	47.2 \pm 0.7	47.4 \pm 0.9	4.7
Cacalol 500 mg/kg	45.9 \pm 0.8	44.5 \pm 1.1	2.1

7.2 REDUCTION OF PLASMA GLUCOSE WITH EPICACALONE, CACALONE AND COMPOUND 3

This example illustrates the beneficial effects of the pure compounds epicacalone, cacalone, compound 3 and cacalol in reducing plasma glucose levels in obese diabetic *ob/ob* mice.

7.2.1 MATERIALS AND METHODS

Using methods more fully described in Section 7.1.1 above, diabetic *ob/ob* mice (8 animals/group) were dosed with single oral doses with either vehicle, epicacalone, cacalone, compound 3 or cacalol at a molar equivalent dose of 1090 $\mu\text{mol/kg/day}$, or metformin at 250 mg (1510 μmol)/kg/day. Blood was sampled from the tail vein 3 h post dosing, and analyzed for plasma glucose levels as before. Individual body weights and mean food consumption (each cage) were also measured after 24 h. Epicacalone, cacalone, compound 3 and cacalol were purified as described in Section 6.3, above.

7.2.2 RESULTS

Single doses of compound 3 or cacalol (1090 $\mu\text{mol/kg/day/kg}$) given to diabetic C57Bl/6J *ob/ob* mice resulted in significant reductions in plasma glucose relative to vehicle controls 3 h after oral administration, while all compounds resulted in a statistically significant reduction in glucose levels relative to control values by 24 h after a single dose (Fig. 2). Three hours after dosing, glucose levels declined 110 and 124 mg/dL for compound 3 ($P < 0.0016$) and cacalol ($P < 0.0005$), respectively, from the baseline values. By comparison, the known hypoglycemic agent metformin caused a reduction in plasma glucose levels of 152 mg/dL ($P < 0.0001$). Over the 3 h test period, there was a reduction in plasma glucose levels in vehicle controls of 35 mg/dL, a value that was not statistically significant. Body weights and food consumption were not adversely affected for any treatment groups during the test period (Table 4).

Although epicacalone and cacalone did not result in substantial reductions in plasma glucose by the 3 h time period under the conditions of this experiment, epicacalone and cacalone do result in increased glucose transport *in vitro*; an art recognized *in vitro* system that represents an important mode of action for glucose utilization and disposal in mammals. Additionally, it would be recognized by those skilled in the art that under the conditions in which these compounds were evaluated *in vivo*, i.e., a single dose, differences in pharmacokinetics, absorption, or pharmacology could explain the reduced activity compared to compound 3 and cacalol.

Table 4

Effect of Epicacalone, Cacalone, Compound 3, and Cacalol on Body Weight and Food Consumption

TREATMENT	Body weight (g/mouse) (mean \pm sem)	Body weight (g/mouse) (mean \pm sem)	Food Intake (g/mouse)
	0 h	24 hr	0-24 h
Vehicle	44.1 \pm 0.8	44.1 \pm 0.8	5.1
Metformin 250 mg/kg	43.5 \pm 0.4	43.2 \pm 0.5	4.5
Epicacalone 267 mg/kg	44.1 \pm 1.6	43.3 \pm 1.5	4.0
Cacalone 267 mg/kg	41.6 \pm 0.9	41.4 \pm 0.9	4.8
Compound 3 285 mg/kg	42.9 \pm 1.2	42.6 \pm 1.2	4.8
Cacalol 250 mg/kg	44.1 \pm 0.8	43.5 \pm 0.7	4.1

7.3 REDUCTION OF PLASMA GLUCOSE WITH DIMATURIN

This example illustrates the beneficial effects of pure compound dimaturin in reducing plasma glucose levels in obese diabetic *ob/ob* mice.

7.3.1 MATERIALS AND METHODS

Using methods more fully described in Section 7.1.1 above, diabetic *ob/ob* mice (8 animals/group) were dosed with single oral doses with either vehicle, dimaturin at doses of 5 250 mg (0.48 mmol)/kg/day, or metformin at 250 mg (1.51 mmol)/kg/day. Blood was sampled from the tail vein 3 h post dosing, and analyzed for plasma glucose levels as before. Individual body weights and mean food consumption (each cage) were also measured after 24 h. Dimaturin was purified as 10 described previously in Section 6.3.

7.3.2. RESULTS

As illustrated in Fig. 3, a single dose of dimaturin given to diabetic C57Bl/6J *ob/ob* mice given at a 15 level of 0.48 mmol/kg resulted in significant reductions in plasma glucose relative to vehicle controls 3 h after oral administration, while glucose levels returned to baseline values by 24 h. Three hours after dosing, glucose levels declined 45 mg/dL for dimaturin ($p=0.0031$) from the baseline 20 value. By comparison, the known hypoglycemic agent metformin caused a reduction in plasma glucose levels of 135 mg/dL ($p<0.0001$). Over the 3 h test period, there was an increase in plasma glucose levels in vehicle controls of 45 mg/dL, a value that is not statistically significant. Body weights 25 and food consumption were not adversely affected for any treatment groups during the test period.

These data indicate that dimaturin is an effective oral anti-hyperglycemic agent in a rodent model of insulin resistance, obesity, and NIDDM.

30

8. EXAMPLE: STIMULATION OF GLUCOSE TRANSPORT

This example illustrates the ability of epicacalone and cacalone to directly stimulate glucose transport in 3T3-L1 adipocytes, an art recognized *in vitro* system that 35 represents an important mode of action for glucose utilization and disposal (i.e., transfer of plasma glucose to surrounding tissues) in mammals. Metformin, a drug that

enhances glucose disposal and one that is currently used to treat NIDDM, exhibits significant stimulatory activity in this model system.

5

8.1 MATERIALS AND METHODS

Murine 3T3-L1 preadipocytes (American Type Culture Collection CL 173) were maintained in Dulbecco's modified Eagles medium (DMEM) containing 10% (v/v) supplemented calf serum, antibiotics, and 25 mM glucose. Cells were seeded in 24-well cluster plates (10,000 cells/well), grown to confluence (typically 5 days), and induced to differentiate 2 days post-confluence (day 0) according to the standard protocol of Frost and Lane [Frost, S. and Lane, M.D. (1985) *J. Biol. Chem.* 260, 2646-2652]. Following differentiation, adipocytes were maintained in DMEM containing 10% fetal bovine serum, and provided with fresh medium every 2-3 days. Adipocytes employed in this study were used on days 7-10 post-differentiation. On the day of the experiment, adipocytes were washed with phosphate-buffered saline and switched to serum-free DMEM medium. Adipocytes were treated (in triplicate) for 18 hr with the indicated concentrations of epicacalone, cacalone, or metformin. Concentrated stock solutions of epicacalone and cacalone were freshly prepared in dimethyl sulfoxide (DMSO) and diluted into culture medium. The final concentration of DMSO was 0.2% (v/v) which was also included in basal conditions. Metformin was dissolved directly into culture medium and further diluted into the same medium. Following overnight (18 hr) treatment, the culture medium was aspirated and the monolayers washed with Krebs-Ringer Hepes buffer. To assess the effects of the compounds on basal glucose transport, 2-deoxy-D-glucose uptake (an indicator of glucose transport) was measured in the absence of insulin stimulation. To determine if 18 hr exposure to compounds potentiated the stimulatory effect of insulin, adipocytes were further treated with 0.5 nM insulin (a sub-maximal concentration) for 30 minutes at 37° C. Under these assay conditions, 0.5 nM insulin stimulates glucose

transport by approximately 200-400% over basal (typically 50 nmoles 2-deoxyglucose/10 minutes/well), and 100 nM insulin (a maximally effective concentration) stimulates glucose transport by approximately 1500-2000% over basal. Glucose transport assays were initiated by the addition of 2-deoxy-D-³H]glucose (0.5 μ Ci/ml; 100 μ M final concentrations) to each well followed by incubation for 10 min at 22° C. Assays were terminated by aspirating the media and rapidly washing the monolayer two times with ice-cold phosphate-buffered saline solution. Cell monolayers were solubilized in 0.1N NaOH, transferred to scintillation vials, and radioactivity determined by liquid scintillation counting. All data were corrected for non-specific hexose uptake determined in parallel samples treated for 5 minutes with 200 μ M cytochalasin B.

8.2 RESULTS

Epicacalone and cacalone (100 and 300 μ M) increased the rate of basal glucose transport (*i.e.* no added insulin) in 3T3-L1 adipocytes by approximately 50% (Fig. 4). These compounds were approximately 10 times more potent than metformin, although the magnitude of stimulation in response to metformin was greater (approximately 350% of basal). Epicacalone and cacalone (2-200 μ M) also sensitized the glucose transport system in adipocytes to subsequent stimulation with a sub-maximal concentration of insulin (0.5 nM). Epicacalone and cacalone potentiated glucose transport in response to insulin by approximately 50% at 200 μ M (Fig. 5). The sensitizing effects of epicacalone and cacalone were equivalent in magnitude to those elicited by metformin and were observed at substantially lower concentrations (compared to metformin), further demonstrating the enhanced potency of both epicacalone and cacalone. As would be recognized by those skilled in the art, these data indicate that epicacalone and cacalone directly stimulate glucose transport *in vitro*, an effect that is predicted to result in enhanced glucose disposal and glucose reduction *in vivo*.

The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments which are functionally
5 equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the appended claims.

10 A number of references have been cited and the entire disclosures of which are incorporated herein by reference.

15

20


25

30

35

What is claimed is:

1. A compound having the structure of formula 3:



3

and pharmaceutically acceptable salts thereof.

15 2. The compound of claim 1, wherein the pharmaceutically acceptable salt is selected from the group consisting of sodium, potassium, lithium, calcium, magnesium, zinc and iron.

20 3. A method for reducing the blood glucose of a mammal, comprising administering to said mammal a hypoglycemically effective amount of a composition comprising a compound selected from the group consisting of epicacalone, cacalone, compound 3, cacalol, dimaturin and pharmaceutically
25 acceptable salts thereof.

4. The method of claim 3, wherein the pharmaceutically acceptable salt is selected from the group consisting of sodium, potassium, lithium, calcium, magnesium,
30 zinc and iron.

5. A method for treatment of diabetes mellitus, comprising administering, to a mammal suffering from diabetes mellitus, a therapeutically effective amount of a composition
35 comprising a compound selected from the group consisting of epicacalone, cacalone, compound 3, cacalol, dimaturin and pharmaceutically acceptable salts thereof.

6. The method of claim 5, wherein the pharmaceutically acceptable salt is selected from the group consisting of sodium, potassium, lithium, calcium, magnesium, zinc and iron.

5

7. The method of claim 5, wherein the composition is administered in conjunction with another hypoglycemic agent selected from the group consisting of a sulfonylurea, a biguanide, a thiazolidinedione, a β_3 -adrenoceptor agonist, an α -glycosidase inhibitor and insulin.

8. The method of claim 7, wherein the sulfonylurea is selected from the group consisting of acetohexamide, chlorpropamide, tolazamide, tolbutamide, glyburide, glypizide and glycazide.

9. The method of claim 7, wherein the biguanide is metformin or buformin.

10. The method of claim 7, wherein the α -glucosidase inhibitor is acarbose or miglatol.

11. The method of claim 7, wherein the thiazolidinedione is troglitazone.

25

12. A pharmaceutical composition for use as a hypoglycemic agent in mammals, comprising a therapeutically effective amount of a compound selected from the group consisting of epicacalone, cacalone, compound 3, cacalol, dimaturin and pharmaceutically acceptable salts thereof.

13. The method of claim 12, wherein the pharmaceutically acceptable salt is selected from the group consisting of sodium, potassium, lithium, calcium, magnesium, zinc and iron.

14. A method for reducing the blood glucose in a mammal, comprising administering to a mammal in need of such blood glucose reduction, an effective amount of an extract from *Psacalium spp.* in which said extract was obtained by a
5 process which comprised:

(a) washing plant material from *Psacalium spp.* with a non-polar organic solvent to obtain an organic solution of hypoglycemically active compounds;

(b) concentrating the organic solution to obtain
10 an enriched mixture of hypoglycemically active compounds;

(c) washing the enriched mixture of hypoglycemically active compounds with a biphasic mixture of a polar solvent and a hydrocarbon solvent to obtain a bioactive polar solution, wherein said polar solvent and said
15 bioactive polar solution are immiscible in said hydrocarbon solvent; and

(d) concentrating said bioactive polar solution to obtain an extract useful as a hypoglycemic agent.

20 15. The method of claim 14 wherein said polar solvent is 10% aqueous ethanol.

16. A method for treatment of diabetes mellitus, comprising administering to a mammal suffering from diabetes
25 mellitus a therapeutically active amount of an extract from *Psacalium spp.* in which said extract was obtained by a process which comprised:

(a) washing plant material from *Psacalium spp.* with a non-polar organic solvent to obtain an organic
30 solution of hypoglycemically active compounds;

(b) concentrating the organic solution to obtain an enriched mixture of hypoglycemically active compounds;

(c) washing the enriched mixture of hypoglycemically active compounds with a biphasic mixture of
35 a polar solvent and a hydrocarbon solvent to obtain a bioactive polar solution, wherein said polar solvent and said

bioactive polar solution are immiscible in said hydrocarbon solvent; and

(d) concentrating said bioactive polar solution to obtain an extract useful as a hypoglycemic agent.

5

17. A pharmaceutical composition for use as a hypoglycemic agent in mammals, comprising a therapeutically effective amount of an extract from *Psacalium spp.* in which said extract was obtained by a process which comprised:

10 (a) washing plant material from *Psacalium spp.* with a non-polar organic solvent to obtain an organic solution of hypoglycemically active compounds;

(b) concentrating the organic solution to obtain an enriched mixture of hypoglycemically active compounds;

15 (c) washing the enriched mixture of hypoglycemically active compounds with a biphasic mixture of a polar solvent and a hydrocarbon solvent to obtain a bioactive polar solution, wherein said polar solvent and said bioactive polar solution are immiscible in said hydrocarbon
20 solvent; and

(d) concentrating said bioactive polar solution to obtain an extract useful as a hypoglycemic agent.

18. The composition of claim 17, wherein said
25 polar solvent is 10% aqueous ethanol.

30

35




FIG.1

2/5





FIG.2

3/5



4/5




FIG.4

5/5




FIG.5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/08427**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :C07D 307/92; A61K 31/365

US CL :549/299; 514/468

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : C07D 307/92; A61K 31/365

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN-FIL REG AND CAPLUS FILE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	Chemical Abstracts-Volume 124, issued 1996, Gray et al., "Phytotoxicity of Cacalol and some Derivatives Obtained from the Roots of Psacalium decompositum", abstract no. 124-249846, Journal Chem. Ecology, 22(3), pages 393-403, see entire abstract.	1-18

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

29 JULY 1996

Date of mailing of the international search report

17 SEP 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BERNARD DENTZ

Telephone No. (703) 308-1235